A Novo Nordisk weight-loss drug is safe and effective in children as young as six, according to a new company-funded study, paving the way for liraglutide to become the first treatment for obesity to be made available to the age group.
诺和诺德(Novo Nordisk)资助的一项新研究显示，该公司的一种减肥药对6岁儿童安全有效，这为利拉鲁肽(liraglutide)成为首款用于该年龄组儿童的肥胖症治疗药物铺平了道路。
您已阅读6%（329字），剩余94%（5416字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。